Synthesis and Molecular Modeling of New 1-Aryl-3-[4-arylpiperazin-1-yl]-1-propane Derivatives with High Affinity at the Serotonin Transporter and at 5-HT1A Receptors

It has been proposed that 5-HT1A receptor antagonists augment the antidepressant efficacy of selective serotonin (5-HT) reuptake inhibitors. In a search toward new and efficient antidepressants, 1-(aryl)-3-[4-arylpiperazin-1-yl]-1-propane molecular hybrids were designed, synthesized, and evaluated f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2002-09, Vol.45 (19), p.4128-4139
Hauptverfasser: Orús, Lara, Pérez-Silanes, Silvia, Oficialdegui, Ana-M, Martínez-Esparza, Javier, Del Castillo, Juan-C, Mourelle, Marisa, Langer, Thierry, Guccione, Salvatore, Donzella, Giuseppina, Krovat, Eva M, Poptodorov, Konstantin, Lasheras, Berta, Ballaz, Santiago, Hervías, Isabel, Tordera, Rosa, Del Río, Joaquín, Monge, Antonio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4139
container_issue 19
container_start_page 4128
container_title Journal of medicinal chemistry
container_volume 45
creator Orús, Lara
Pérez-Silanes, Silvia
Oficialdegui, Ana-M
Martínez-Esparza, Javier
Del Castillo, Juan-C
Mourelle, Marisa
Langer, Thierry
Guccione, Salvatore
Donzella, Giuseppina
Krovat, Eva M
Poptodorov, Konstantin
Lasheras, Berta
Ballaz, Santiago
Hervías, Isabel
Tordera, Rosa
Del Río, Joaquín
Monge, Antonio
description It has been proposed that 5-HT1A receptor antagonists augment the antidepressant efficacy of selective serotonin (5-HT) reuptake inhibitors. In a search toward new and efficient antidepressants, 1-(aryl)-3-[4-arylpiperazin-1-yl]-1-propane molecular hybrids were designed, synthesized, and evaluated for 5-HT reuptake inhibition and 5-HT1A receptor affinity. The design was based in coupling structural moieties related to inhibition of serotonin reuptake, such as benzo[b]thiophene derivatives to arylpiperazines, typical 5-HT1A receptor ligands. In binding studies, several compounds showed affinity at the 5-HT transporter and at 5-HT1A receptors. Molecular modeling studies predicted the pharmacophore elements required for high affinity binding and the features that enable to discriminate between agonist, partial agonist, or antagonist action at 5-HT1A receptors and 5-HT transporter inhibition. Solvent interactions in desolvation prior to the binding step along with enthalpy and enthropy compensations might be responsible to explain agonist, partial agonist, and antagonist character. Hydrogen-bonding capability seems to be important to break hydrogen interhelical hydrogen bonds or alternatively to form other bonds upon ligand binding. Partial agonists and antagonists are unable to do this as the full agonist, which interacts closely by long-range forces or directly. The compounds showing the higher affinity at both the 5-HT transporter (K i < 50 nM) and the 5-HT1A receptors (K i < 20 nM) were further explored for their ability to stimulate [35S]GTPγS binding or to antagonize 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT)-stimulated [35]GTPγS binding to rat hippocampal membranes, an index of agonist/antagonist action at 5-HT1A receptors, respectively. Compound 8g exhibited agonist activity (EC50 = 30 nM) in this assay, whereas compounds 7g and 8h,i behaved as weak partial agonists and 7h−j and 8j,l antagonized the R(+)-8-OH-DPAT-stimulated GTPγS binding. Functional characterization was performed by measuring the antagonism to 8-OH-DPAT-induced hypothermia in mice.
doi_str_mv 10.1021/jm0111200
format Article
fullrecord <record><control><sourceid>acs_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_13895141</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>a477679878</sourcerecordid><originalsourceid>FETCH-LOGICAL-a251t-472f4885a3c3473ef4714af883880d169e3a55dfe416585ef0eb87b6ced91c0e3</originalsourceid><addsrcrecordid>eNpFUctuFDEQtCIiZUk45A984Whw-zHjPS6BZBGBIHa5gJDlzLSzXiaeke08lv_hP3EICpfukrpUXaUi5Bj4K-ACXm-vOQAIzvfIDLTgTBmunpEZ50Iw0Qh5QJ7nvOWcSxByRn6vdrFsMIdMXezpx3HA7mZwqaIehxCv6OjpJ7yjwBZpNzDJvivmKprChMn9CpEB2w0_6pzSOLmI9C2mcOtKuMVM70LZ0GW42tCF9yGGsqOu0PqQrjCNZYwh0nVyMU9jKpj-eqgEzZZrWNAv2OFUxpSPyL53Q8YX__Yh-Xr6bn2yZOcXZ-9PFufMCQ2FqVZ4ZYx2spOqlehVC8p5Y6QxvIdmjtJp3XtU0Gij0XO8NO1l02E_h46jPCQvH3Unlzs3-OqsC9lOKVzXzBakmWtQUHnskRdywfunu0s_bdPKVtv155XVH_Q3bk7P7Jv_uq7LdjvepFhTWOD2oTP71Jn8A6vOiD0</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Synthesis and Molecular Modeling of New 1-Aryl-3-[4-arylpiperazin-1-yl]-1-propane Derivatives with High Affinity at the Serotonin Transporter and at 5-HT1A Receptors</title><source>ACS Publications</source><creator>Orús, Lara ; Pérez-Silanes, Silvia ; Oficialdegui, Ana-M ; Martínez-Esparza, Javier ; Del Castillo, Juan-C ; Mourelle, Marisa ; Langer, Thierry ; Guccione, Salvatore ; Donzella, Giuseppina ; Krovat, Eva M ; Poptodorov, Konstantin ; Lasheras, Berta ; Ballaz, Santiago ; Hervías, Isabel ; Tordera, Rosa ; Del Río, Joaquín ; Monge, Antonio</creator><creatorcontrib>Orús, Lara ; Pérez-Silanes, Silvia ; Oficialdegui, Ana-M ; Martínez-Esparza, Javier ; Del Castillo, Juan-C ; Mourelle, Marisa ; Langer, Thierry ; Guccione, Salvatore ; Donzella, Giuseppina ; Krovat, Eva M ; Poptodorov, Konstantin ; Lasheras, Berta ; Ballaz, Santiago ; Hervías, Isabel ; Tordera, Rosa ; Del Río, Joaquín ; Monge, Antonio</creatorcontrib><description>It has been proposed that 5-HT1A receptor antagonists augment the antidepressant efficacy of selective serotonin (5-HT) reuptake inhibitors. In a search toward new and efficient antidepressants, 1-(aryl)-3-[4-arylpiperazin-1-yl]-1-propane molecular hybrids were designed, synthesized, and evaluated for 5-HT reuptake inhibition and 5-HT1A receptor affinity. The design was based in coupling structural moieties related to inhibition of serotonin reuptake, such as benzo[b]thiophene derivatives to arylpiperazines, typical 5-HT1A receptor ligands. In binding studies, several compounds showed affinity at the 5-HT transporter and at 5-HT1A receptors. Molecular modeling studies predicted the pharmacophore elements required for high affinity binding and the features that enable to discriminate between agonist, partial agonist, or antagonist action at 5-HT1A receptors and 5-HT transporter inhibition. Solvent interactions in desolvation prior to the binding step along with enthalpy and enthropy compensations might be responsible to explain agonist, partial agonist, and antagonist character. Hydrogen-bonding capability seems to be important to break hydrogen interhelical hydrogen bonds or alternatively to form other bonds upon ligand binding. Partial agonists and antagonists are unable to do this as the full agonist, which interacts closely by long-range forces or directly. The compounds showing the higher affinity at both the 5-HT transporter (K i &lt; 50 nM) and the 5-HT1A receptors (K i &lt; 20 nM) were further explored for their ability to stimulate [35S]GTPγS binding or to antagonize 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT)-stimulated [35]GTPγS binding to rat hippocampal membranes, an index of agonist/antagonist action at 5-HT1A receptors, respectively. Compound 8g exhibited agonist activity (EC50 = 30 nM) in this assay, whereas compounds 7g and 8h,i behaved as weak partial agonists and 7h−j and 8j,l antagonized the R(+)-8-OH-DPAT-stimulated GTPγS binding. Functional characterization was performed by measuring the antagonism to 8-OH-DPAT-induced hypothermia in mice.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm0111200</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Biological and medical sciences ; Medical sciences ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Pharmacology. Drug treatments ; Serotoninergic system</subject><ispartof>Journal of medicinal chemistry, 2002-09, Vol.45 (19), p.4128-4139</ispartof><rights>Copyright © 2002 American Chemical Society</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm0111200$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm0111200$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,777,781,27057,27905,27906,56719,56769</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13895141$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Orús, Lara</creatorcontrib><creatorcontrib>Pérez-Silanes, Silvia</creatorcontrib><creatorcontrib>Oficialdegui, Ana-M</creatorcontrib><creatorcontrib>Martínez-Esparza, Javier</creatorcontrib><creatorcontrib>Del Castillo, Juan-C</creatorcontrib><creatorcontrib>Mourelle, Marisa</creatorcontrib><creatorcontrib>Langer, Thierry</creatorcontrib><creatorcontrib>Guccione, Salvatore</creatorcontrib><creatorcontrib>Donzella, Giuseppina</creatorcontrib><creatorcontrib>Krovat, Eva M</creatorcontrib><creatorcontrib>Poptodorov, Konstantin</creatorcontrib><creatorcontrib>Lasheras, Berta</creatorcontrib><creatorcontrib>Ballaz, Santiago</creatorcontrib><creatorcontrib>Hervías, Isabel</creatorcontrib><creatorcontrib>Tordera, Rosa</creatorcontrib><creatorcontrib>Del Río, Joaquín</creatorcontrib><creatorcontrib>Monge, Antonio</creatorcontrib><title>Synthesis and Molecular Modeling of New 1-Aryl-3-[4-arylpiperazin-1-yl]-1-propane Derivatives with High Affinity at the Serotonin Transporter and at 5-HT1A Receptors</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>It has been proposed that 5-HT1A receptor antagonists augment the antidepressant efficacy of selective serotonin (5-HT) reuptake inhibitors. In a search toward new and efficient antidepressants, 1-(aryl)-3-[4-arylpiperazin-1-yl]-1-propane molecular hybrids were designed, synthesized, and evaluated for 5-HT reuptake inhibition and 5-HT1A receptor affinity. The design was based in coupling structural moieties related to inhibition of serotonin reuptake, such as benzo[b]thiophene derivatives to arylpiperazines, typical 5-HT1A receptor ligands. In binding studies, several compounds showed affinity at the 5-HT transporter and at 5-HT1A receptors. Molecular modeling studies predicted the pharmacophore elements required for high affinity binding and the features that enable to discriminate between agonist, partial agonist, or antagonist action at 5-HT1A receptors and 5-HT transporter inhibition. Solvent interactions in desolvation prior to the binding step along with enthalpy and enthropy compensations might be responsible to explain agonist, partial agonist, and antagonist character. Hydrogen-bonding capability seems to be important to break hydrogen interhelical hydrogen bonds or alternatively to form other bonds upon ligand binding. Partial agonists and antagonists are unable to do this as the full agonist, which interacts closely by long-range forces or directly. The compounds showing the higher affinity at both the 5-HT transporter (K i &lt; 50 nM) and the 5-HT1A receptors (K i &lt; 20 nM) were further explored for their ability to stimulate [35S]GTPγS binding or to antagonize 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT)-stimulated [35]GTPγS binding to rat hippocampal membranes, an index of agonist/antagonist action at 5-HT1A receptors, respectively. Compound 8g exhibited agonist activity (EC50 = 30 nM) in this assay, whereas compounds 7g and 8h,i behaved as weak partial agonists and 7h−j and 8j,l antagonized the R(+)-8-OH-DPAT-stimulated GTPγS binding. Functional characterization was performed by measuring the antagonism to 8-OH-DPAT-induced hypothermia in mice.</description><subject>Biological and medical sciences</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Pharmacology. Drug treatments</subject><subject>Serotoninergic system</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNpFUctuFDEQtCIiZUk45A984Whw-zHjPS6BZBGBIHa5gJDlzLSzXiaeke08lv_hP3EICpfukrpUXaUi5Bj4K-ACXm-vOQAIzvfIDLTgTBmunpEZ50Iw0Qh5QJ7nvOWcSxByRn6vdrFsMIdMXezpx3HA7mZwqaIehxCv6OjpJ7yjwBZpNzDJvivmKprChMn9CpEB2w0_6pzSOLmI9C2mcOtKuMVM70LZ0GW42tCF9yGGsqOu0PqQrjCNZYwh0nVyMU9jKpj-eqgEzZZrWNAv2OFUxpSPyL53Q8YX__Yh-Xr6bn2yZOcXZ-9PFufMCQ2FqVZ4ZYx2spOqlehVC8p5Y6QxvIdmjtJp3XtU0Gij0XO8NO1l02E_h46jPCQvH3Unlzs3-OqsC9lOKVzXzBakmWtQUHnskRdywfunu0s_bdPKVtv155XVH_Q3bk7P7Jv_uq7LdjvepFhTWOD2oTP71Jn8A6vOiD0</recordid><startdate>20020912</startdate><enddate>20020912</enddate><creator>Orús, Lara</creator><creator>Pérez-Silanes, Silvia</creator><creator>Oficialdegui, Ana-M</creator><creator>Martínez-Esparza, Javier</creator><creator>Del Castillo, Juan-C</creator><creator>Mourelle, Marisa</creator><creator>Langer, Thierry</creator><creator>Guccione, Salvatore</creator><creator>Donzella, Giuseppina</creator><creator>Krovat, Eva M</creator><creator>Poptodorov, Konstantin</creator><creator>Lasheras, Berta</creator><creator>Ballaz, Santiago</creator><creator>Hervías, Isabel</creator><creator>Tordera, Rosa</creator><creator>Del Río, Joaquín</creator><creator>Monge, Antonio</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope></search><sort><creationdate>20020912</creationdate><title>Synthesis and Molecular Modeling of New 1-Aryl-3-[4-arylpiperazin-1-yl]-1-propane Derivatives with High Affinity at the Serotonin Transporter and at 5-HT1A Receptors</title><author>Orús, Lara ; Pérez-Silanes, Silvia ; Oficialdegui, Ana-M ; Martínez-Esparza, Javier ; Del Castillo, Juan-C ; Mourelle, Marisa ; Langer, Thierry ; Guccione, Salvatore ; Donzella, Giuseppina ; Krovat, Eva M ; Poptodorov, Konstantin ; Lasheras, Berta ; Ballaz, Santiago ; Hervías, Isabel ; Tordera, Rosa ; Del Río, Joaquín ; Monge, Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a251t-472f4885a3c3473ef4714af883880d169e3a55dfe416585ef0eb87b6ced91c0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Biological and medical sciences</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Pharmacology. Drug treatments</topic><topic>Serotoninergic system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Orús, Lara</creatorcontrib><creatorcontrib>Pérez-Silanes, Silvia</creatorcontrib><creatorcontrib>Oficialdegui, Ana-M</creatorcontrib><creatorcontrib>Martínez-Esparza, Javier</creatorcontrib><creatorcontrib>Del Castillo, Juan-C</creatorcontrib><creatorcontrib>Mourelle, Marisa</creatorcontrib><creatorcontrib>Langer, Thierry</creatorcontrib><creatorcontrib>Guccione, Salvatore</creatorcontrib><creatorcontrib>Donzella, Giuseppina</creatorcontrib><creatorcontrib>Krovat, Eva M</creatorcontrib><creatorcontrib>Poptodorov, Konstantin</creatorcontrib><creatorcontrib>Lasheras, Berta</creatorcontrib><creatorcontrib>Ballaz, Santiago</creatorcontrib><creatorcontrib>Hervías, Isabel</creatorcontrib><creatorcontrib>Tordera, Rosa</creatorcontrib><creatorcontrib>Del Río, Joaquín</creatorcontrib><creatorcontrib>Monge, Antonio</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Orús, Lara</au><au>Pérez-Silanes, Silvia</au><au>Oficialdegui, Ana-M</au><au>Martínez-Esparza, Javier</au><au>Del Castillo, Juan-C</au><au>Mourelle, Marisa</au><au>Langer, Thierry</au><au>Guccione, Salvatore</au><au>Donzella, Giuseppina</au><au>Krovat, Eva M</au><au>Poptodorov, Konstantin</au><au>Lasheras, Berta</au><au>Ballaz, Santiago</au><au>Hervías, Isabel</au><au>Tordera, Rosa</au><au>Del Río, Joaquín</au><au>Monge, Antonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis and Molecular Modeling of New 1-Aryl-3-[4-arylpiperazin-1-yl]-1-propane Derivatives with High Affinity at the Serotonin Transporter and at 5-HT1A Receptors</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2002-09-12</date><risdate>2002</risdate><volume>45</volume><issue>19</issue><spage>4128</spage><epage>4139</epage><pages>4128-4139</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>It has been proposed that 5-HT1A receptor antagonists augment the antidepressant efficacy of selective serotonin (5-HT) reuptake inhibitors. In a search toward new and efficient antidepressants, 1-(aryl)-3-[4-arylpiperazin-1-yl]-1-propane molecular hybrids were designed, synthesized, and evaluated for 5-HT reuptake inhibition and 5-HT1A receptor affinity. The design was based in coupling structural moieties related to inhibition of serotonin reuptake, such as benzo[b]thiophene derivatives to arylpiperazines, typical 5-HT1A receptor ligands. In binding studies, several compounds showed affinity at the 5-HT transporter and at 5-HT1A receptors. Molecular modeling studies predicted the pharmacophore elements required for high affinity binding and the features that enable to discriminate between agonist, partial agonist, or antagonist action at 5-HT1A receptors and 5-HT transporter inhibition. Solvent interactions in desolvation prior to the binding step along with enthalpy and enthropy compensations might be responsible to explain agonist, partial agonist, and antagonist character. Hydrogen-bonding capability seems to be important to break hydrogen interhelical hydrogen bonds or alternatively to form other bonds upon ligand binding. Partial agonists and antagonists are unable to do this as the full agonist, which interacts closely by long-range forces or directly. The compounds showing the higher affinity at both the 5-HT transporter (K i &lt; 50 nM) and the 5-HT1A receptors (K i &lt; 20 nM) were further explored for their ability to stimulate [35S]GTPγS binding or to antagonize 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT)-stimulated [35]GTPγS binding to rat hippocampal membranes, an index of agonist/antagonist action at 5-HT1A receptors, respectively. Compound 8g exhibited agonist activity (EC50 = 30 nM) in this assay, whereas compounds 7g and 8h,i behaved as weak partial agonists and 7h−j and 8j,l antagonized the R(+)-8-OH-DPAT-stimulated GTPγS binding. Functional characterization was performed by measuring the antagonism to 8-OH-DPAT-induced hypothermia in mice.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><doi>10.1021/jm0111200</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2002-09, Vol.45 (19), p.4128-4139
issn 0022-2623
1520-4804
language eng
recordid cdi_pascalfrancis_primary_13895141
source ACS Publications
subjects Biological and medical sciences
Medical sciences
Neuropharmacology
Neurotransmitters. Neurotransmission. Receptors
Pharmacology. Drug treatments
Serotoninergic system
title Synthesis and Molecular Modeling of New 1-Aryl-3-[4-arylpiperazin-1-yl]-1-propane Derivatives with High Affinity at the Serotonin Transporter and at 5-HT1A Receptors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T02%3A22%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20and%20Molecular%20Modeling%20of%20New%201-Aryl-3-%5B4-arylpiperazin-1-yl%5D-1-propane%20Derivatives%20with%20High%20Affinity%20at%20the%20Serotonin%20Transporter%20and%20at%205-HT1A%20Receptors&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Or%C3%BAs,%20Lara&rft.date=2002-09-12&rft.volume=45&rft.issue=19&rft.spage=4128&rft.epage=4139&rft.pages=4128-4139&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm0111200&rft_dat=%3Cacs_pasca%3Ea477679878%3C/acs_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true